Leverage Cytel's Pioneering Model-Informed Drug Development (MIDD)
Harness Cytel’s cutting-edge MIDD expertise to optimize your drug development, for more precise, efficient and successful clinical outcomes.
Model-Informed Drug Development at Cytel
In the vanguard of clinical advancement, Cytel’s Model-Informed Drug Development (MIDD) uses sophisticated modeling and simulation to inform and optimize your trial strategy. MIDD leverages powerful computational simulations to predict drug efficacy and safety, offering an empirical basis for key development decisions. Cytel’s seasoned biostatisticians combine rigorous analytical methods with deep therapeutic knowledge, transforming traditional drug development into a more precise and predictive science. We empower your team with actionable insights to increase your probability of clinical success, which is especially critical when dealing with ethical and methodological challenges.
Contact usStrategic optimization
Cytel’s MIDD provides strategic clarity, enhancing trial design with predictive models that streamline your drug development pathways.
Regulatory foresight
Leverage Cytel’s regulatory insight to anticipate and address potential challenges, smoothing the pathway for approvals.
Computational proficiency
Maximize your trial efficiency with Cytel’s computational prowess, rapidly simulating scenarios to find the optimal study design.
Risk mitigation
Our MIDD can reduce uncertainty and mitigate risk allowing you to make informed decisions for robust clinical trial execution.
Optimizing Drug Development with MIDD
MIDD harnesses mathematical modeling and simulations to refine your drug development and regulatory strategies. Integrating pharmacokinetic, pharmacodynamic, and patient data, MIDD enhances decision-making, predicting drug responses and informing clinical trial designs.
Cytel’s innovative approach brings extensive biostatistical expertise and advanced analytics to support your strategic drug development. Our experience in MIDD positions us as a pivotal partner in optimizing your drug development pathway, facilitating efficient and informed decisions that accelerate bringing therapies to market.
Transforming MIDD with Our Flagship Analytical Software
Our East Horizon Platform (a merge of our East® and Solara® software) stands at the heart of Cytel’s model-informed drug development, embodying a powerful, user-friendly tool for simulation and analysis. Tailored to drug development, our platform enables comprehensive scenario testing to generate insights that refine dosing strategies and increase the predictive accuracy of clinical outcomes. It embodies our commitment to precision and efficiency, allowing you to navigate the complexities of clinical trials with confidence.
MIDD is poised to become the linchpin in the evolution of drug discovery and development. Cytel is at the forefront, driving MIDD to harness unprecedented computational capabilities and enabling more sophisticated predictive models across all therapeutic areas. Our commitment to innovation propels the adoption of MIDD, offering you a glimpse into a future where drug development is more efficient, less risky, and strategically streamlined. As computational technology advances, Cytel continues to refine MIDD’s potential, ensuring it becomes an indispensable asset in the quest for novel therapies.
Learn MoreAdvancing Rare Disease Treatment with Cytel's MIDD
In the realm of rare diseases, precision is paramount. Cytel’s MIDD capabilities provide a beacon of hope where patient populations are small and diverse. Our robust modeling and simulation techniques help you refine clinical trial designs by focusing on the unique pharmacokinetics and pharmacodynamics often found in rare conditions.
Our East Horizon software platform enhances these efforts, offering you a predictive platform to simulate multiple trial scenarios, invaluable for diseases where every patient counts. Cytel’s dedication to rare diseases is not just about advancing clinical research—it’s about changing lives with each groundbreaking therapy we help bring to market.
Learn More
Webinar
Watch our webinar on Using Cloud-Based Simulation Software to Optimize a Phase II Dose Finding Study.
Watch the webinar
20%
Reduction in overall timelines for clinical trials with MIDD.
>90%
Of recent novel drug approvals utilized modelling and simulation
100,000
Up to 100,000 designs per study with our East Horizon software platform
Related Insights
Industry Voices: Yannis Jemiai on Simulation-Guided Design and the Changing Landscape of Clinical Trial Strategy
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug's probability of success and plot a clearer route to market.